In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read MoreIn a nutshell This study investigated the effects of different chemotherapies on the survival outcomes of elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CHOP treatment is associated with very good survival in elderly patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read More
In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with non-Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read More
In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read More
In a nutshell This article reviewed the front-line treatment options for elderly (65 years or older) patients with mantle cell lymphoma. Some background For older patients with mantle cell lymphoma, the goals of front-line treatment vary. More intense treatments such as chemotherapy can help achieve remission and improve survival. However, frail...
Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of mantle cell lymphoma. This study concluded that this regimen improved outcomes in patients with mantle cell lymphoma. Some background The standard treatment for mantle cell lymphoma (MCL)...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read MoreIn a nutshell This study investigated the effectiveness of stem cell transplantation in follicular lymphoma patients who experienced early treatment failure after frontline chemoimmunotherapy. This study concluded that transplants using the patient's own stem cells or those from a matched sibling donor lead to better survival outcomes in these...
Read MoreIn a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...
Read MoreIn a nutshell This study examined whether newer therapies for non-Hodgkin lymphoma (NHL) were associated with higher odds of negative side effects in older patients. The study concluded that NHL patients over age 65 experienced more serious side effects than younger patients, and these side effects were associated with worse outcomes. Some background...
Read More
In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...
Read More
In a nutshell This study investigated the safety and effectiveness of a chemotherapy regimen alternating R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-cytarabine (rituximab combined with cytarabine) for mantle cell lymphoma (MCL) patients ineligible for stem cell transplant (SCT). This study concluded that alternating...
Read More
